All regulatory updates
718 results found
Nevada Board of Pharmacy posted notice of hearing on proposed amendment to add dipentylone and seven fentanyl-related substances to Schedule I (NAC 453.510)
The Nevada State Board of Pharmacy issued a public hearing notice for LCB File No. R107-25 proposing to amend NAC 453.510 (Schedule I) to add dipentylone and seven fentanyl-related substances to Nevada Schedule I, described as being in conformity with federal regulations. The notice sets a public hearing date of March 5, 2026. If adopted, these additions would expand Nevada’s Schedule I list and affect controlled-substance compliance obligations under NRS 453/NAC 453 for any entities that may encounter these substances (e.g., healthcare, pharmacy, laboratories, enforcement, and supply chain controls).
Secretariat invites submissions of new information/comments on indicative lists for LC‑PFCAs, PFOA and PFHxS listings
The Stockholm Convention Secretariat issued an invitation to submit new information/comments on indicative lists for substances covered by existing PFAS-related listings (long-chain perfluorocarboxylic acids (LC‑PFCAs), PFOA, and PFHxS). Indicative lists help clarify scope for listed substances and related compounds, supporting implementation and enforcement. Compliance teams should review these developments because changes/clarifications to indicative lists can affect substance identification, supply-chain declarations, and compliance determinations for PFAS-related chemicals and articles.
Stockholm Convention Secretariat invites submissions/comments on indicative lists for LC‑PFCAs (and related PFAS listings)
The Stockholm Convention Secretariat issued a communication (dated 28 Jan 2026) inviting Parties and other stakeholders to submit new information and comments on the indicative lists of substances covered by the listings of long-chain perfluorocarboxylic acids (LC‑PFCAs), their salts and related compounds (and also referencing indicative lists for other listed PFAS such as PFOA and PFHxS). This is compliance-relevant because indicative lists affect practical scope interpretation (which specific substances/precursors are considered covered), impacting product stewardship, supply-chain substance identification, and import/export controls under national implementations of the Convention listings.
Nevada Board of Pharmacy notice of hearing: proposed NAC 453.510 Schedule I additions (dipentylone + seven fentanyl-related substances)
The Nevada State Board of Pharmacy issued a Notice of Intent to Act Upon a Regulation / Notice of Hearing (LCB File No. R107-25) proposing to amend NAC 453.510 (Schedule I) to add dipentylone and seven fentanyl-related substances to Nevada Schedule I, stated to be in conformity with federal regulations. A public hearing is scheduled for March 5, 2026, and written comments are due on or before March 5, 2026. Compliance teams should monitor this rulemaking because, if adopted, the substances would become explicitly controlled under Nevada Schedule I, affecting handling prohibitions/controls, registration, security, and recordkeeping obligations under NRS/NAC 453 for registrants and other regulated entities.
Secretariat requests new information/comments on indicative lists for LC‑PFCAs, PFOA and PFHxS listings
The Stockholm Convention Secretariat invited submission of new information and comments on indicative lists of substances covered by existing POP listings for long-chain perfluorocarboxylic acids (LC‑PFCAs), their salts and related compounds; PFOA, its salts and PFOA-related compounds; and PFHxS, its salts and PFHxS-related compounds. These indicative lists support consistent interpretation of listing scope across Parties and can affect compliance determinations (e.g., whether specific PFAS are considered covered).
Stockholm Convention Secretariat requests information/comments on indicative lists for LC‑PFCAs, PFOA and PFHxS listings
The Stockholm Convention Secretariat issued an invitation to submit new information and comments on indicative lists clarifying substances covered by existing Stockholm Convention PFAS-related listings: long-chain perfluorocarboxylic acids (LC‑PFCAs), their salts and related compounds; perfluorooctanoic acid (PFOA), its salts and PFOA-related compounds; and perfluorohexane sulfonic acid (PFHxS), its salts and PFHxS-related compounds. This process supports interpretation of listing scope and can affect compliance screening, product stewardship, and reporting against covered ‘related compounds’.
Stockholm Convention Secretariat requests information/comments on indicative lists for LC‑PFCAs, PFOA and PFHxS listings
The Secretariat invited submission of new information and comments on revised/updated indicative lists clarifying which substances are covered by the Stockholm Convention listings for long-chain perfluorocarboxylic acids (LC‑PFCAs), perfluorooctanoic acid (PFOA), and perfluorohexane sulfonic acid (PFHxS), including their salts and related compounds. These indicative lists can materially affect compliance screening and supply-chain declarations by clarifying scope (e.g., related compounds/precursors) for already-listed POPs.
Nevada Board of Pharmacy proposes adding dipentylone and seven fentanyl-related substances to Schedule I (NAC 453.510)
The Nevada State Board of Pharmacy issued a Notice of Hearing/Intent to act upon a regulation proposing amendments to NAC 453.510 (Schedule I) to add dipentylone and seven fentanyl-related substances to Nevada’s Schedule I list under the Uniform Controlled Substances Act framework. The notice schedules a public hearing (March 5, 2026). If adopted, these substances would become subject to Schedule I restrictions, affecting controlled substance compliance programs (e.g., prohibitions/controls on possession, handling, distribution, and associated enforcement exposure).
Nevada Board of Pharmacy opens public hearing on proposed NAC 453.510 Schedule I additions (dipentylone + seven fentanyl-related substances)
The Nevada State Board of Pharmacy posted a Notice of Intent to act upon a regulation and scheduled a public hearing to amend NAC 453.510 (Schedule I) to add dipentylone and seven fentanyl-related substances to Nevada Schedule I, stated as conforming with federal Uniform Controlled Substances Act scheduling. If adopted, these substances would become Schedule I controlled substances in Nevada, impacting screening, handling/registration controls, and potential enforcement risk for entities that manufacture, distribute, dispense, or otherwise handle controlled substances in Nevada. The notice also sets the opportunity for stakeholder participation via the hearing and written comments.
Singapore NEA circular updates phase‑out/ban date and trade controls for chlorpyrifos, MCCPs (≥45% Cl by weight) and LC‑PFCAs
Singapore’s National Environment Agency (NEA) issued Circular NEA/HS/6.6/SC02 (26 Jan 2026) confirming that from 16 Dec 2026 Singapore will not allow the manufacture, import, or export of chlorpyrifos; medium-chain chlorinated paraffins (MCCPs; C14–C17 with chlorination level ≥45% chlorine by weight); and long-chain perfluorocarboxylic acids (LC‑PFCAs; C9–C21), their salts and related compounds, including products containing these chemicals. The circular ties the prohibition timeline to the Stockholm Convention depositary notification (communicated 16 Dec 2025) and the Convention’s one-year entry-into-force rule. It also describes trade controls for permit declarations (HS codes/product codes in TradeNet) and indicates that permit applications will be subject to CCMD approval; stock depletion is allowed for stocks imported before 16 Dec 2026. Compliance teams should plan for a hard stop on regulated cross-border movements/manufacture by 16 Dec 2026 and ensure customs declaration processes (codes/approval workflows) are ready ahead of the deadline.
Singapore NEA circular announces phase‑out/ban of chlorpyrifos, MCCPs (≥45% chlorine by weight) and LC‑PFCAs (C9–C21) from 16 Dec 2026 (including products containing them)
Singapore’s National Environment Agency (NEA) issued an industry circular titled “Updates on the phase-out of chlorpyrifos, MCCPs (chlorination levels ≥45% chlorine by weight), and LC‑PFCAs under the Stockholm Convention.” The circular states that from 16 Dec 2026, the manufacture, import and export of these POPs—and products containing them—will not be allowed in Singapore. It also notes that stock depletion is allowed for stocks imported before 16 Dec 2026, and that traders must use specified HS codes and NEA product codes in TradeNet permit applications (subject to Chemical Control & Management Department approval). Compliance teams should assess affected products/mixtures, update import/export classifications and permitting processes, and plan supply chain substitutions ahead of the 16 Dec 2026 cutoff.
Singapore NEA circular updates phase‑out/ban date and trade controls for chlorpyrifos, MCCPs (≥45% chlorine by weight) and LC‑PFCAs
Singapore’s National Environment Agency (NEA) issued an official circular to traders/declaring agents updating Singapore’s control measures implementing the Stockholm Convention listings for chlorpyrifos, medium-chain chlorinated paraffins (MCCPs; C14–C17 with chlorination level ≥45% chlorine by weight), and long-chain perfluorocarboxylic acids (LC‑PFCAs; C9–C21), their salts and related compounds. The circular states that from 16 Dec 2026, manufacture, import, and export of these substances and products containing them will not be allowed; however, depletion of existing stocks/products imported before 16 Dec 2026 is permitted. The circular also provides customs/trade implementation details (HS codes/product codes) for TradeNet permit declarations and notes permits are subject to Chemical Control & Management Department (CCMD) approval. NEA indicates it is reviewing applicability of Stockholm Convention exemptions for local industry and will communicate any Singapore-applicable exemptions later.
Singapore NEA circular updates phase‑out/ban of chlorpyrifos, MCCPs (≥45% chlorine by weight) and LC‑PFCAs from 16 Dec 2026
Singapore NEA issued a hazardous substances control circular providing implementation details for Stockholm Convention POP listings covering chlorpyrifos, MCCPs (defined in the circular as C14–C17 with chlorination levels ≥45% chlorine by weight) and LC‑PFCAs (C9–C21), including products containing these chemicals. The circular states that from 16 December 2026, manufacture, import and export will not be allowed (subject to any applicable exemptions to be clarified). It also indicates TradeNet permit declarations/approvals will be impacted and includes annex information (e.g., HS/product codes) that compliance teams can use to screen shipments and update customs/trade controls and product stewardship processes.
EPA publishes latest TSCA Inventory update (biannual public non-confidential Inventory refresh)
EPA posted an updated “Now Available: Latest Update to the TSCA Inventory” notice indicating the latest biannual refresh of the public (non-confidential) TSCA Inventory dataset. The notice describes updates to items such as commercial activity information, unique identifiers, and regulatory flags (e.g., SNURs/test orders). Compliance teams should refresh internal inventory screening datasets and re-check regulatory flags for substances used/imported, particularly for downstream SNUR/test-order indicators.
EPA posts latest TSCA Inventory update notice (page updated Jan. 23, 2026)
EPA posted a notice that the latest biannual TSCA Chemical Substance Inventory update has been released. The notice indicates updates to Inventory-related metadata (e.g., activity data/unique identifiers/regulatory flags) and continued movement of some substances from the confidential to the public portion as part of TSCA CBI review efforts. Compliance teams should refresh internal Inventory reference datasets used to confirm Inventory status and related flags when screening substances for U.S. manufacture/import.
EPA OTAQ updates BABA Implementation Procedures (FAQ memo) for OTAQ federal financial assistance programs
EPA’s Office of Transportation and Air Quality (OTAQ) issued an updated BABA Implementation Procedures document (FAQ/memo format) for OTAQ federal financial assistance programs (including DERA, Clean School Bus, Clean Ports, and Clean Heavy-Duty Vehicles). The update provides program-specific interpretive guidance on BABA applicability and scope (including Purpose-Time-Place concepts), covered product category definitions (iron/steel vs. manufactured products vs. construction materials), compliance documentation/recordkeeping expectations, and waiver usage pathways. The memo includes clarifications relevant to infrastructure vs. rolling stock/equipment (e.g., it states BABA applies to clean/zero-emission school bus infrastructure but not to the bus itself), supporting recipient/contractor specification writing and audit readiness.
Nevada adopts NAC 453.510 Schedule I additions: ethylphenidate and 2‑methyl AP‑237 (R204-24)
Nevada State Board of Pharmacy adoption documentation (R204-24) indicates NAC 453.510 (Schedule I) was amended to add ethylphenidate and 2‑methyl AP‑237 to Nevada’s Schedule I list, as part of maintaining conformity with controlled-substance scheduling under Nevada’s Uniform Controlled Substances Act framework. Compliance impact: regulated Nevada handlers must update controlled-substance controls (inventory, access, procurement, analytical standards, and related compliance documentation) to reflect Schedule I status for these substances under state law.
Nevada Board of Pharmacy adopted NAC 453.510 amendment adding ethylphenidate and 2‑methyl AP‑237 to Schedule I
An informational statement for an adopted Nevada State Board of Pharmacy regulation reports an amendment to NAC 453.510 (Schedule I) adding ethylphenidate and 2‑methyl AP‑237 to Nevada’s Schedule I list. These additions expand substances regulated as Schedule I under Nevada’s Uniform Controlled Substances Act implementation, affecting compliance for any organization potentially encountering these substances (e.g., prohibitions and controls related to possession, distribution, and enforcement consequences). The document states the change is intended to keep Nevada in conformity with federal controlled substance scheduling.
Nevada Board of Pharmacy informational statement indicates adopted NAC 453.510 amendment adding ethylphenidate and 2‑methyl AP‑237 to Schedule I
An informational statement dated January 21, 2026 describes an adopted Nevada State Board of Pharmacy regulation amending NAC 453.510 (Schedule I) to add ethylphenidate and 2‑methyl AP‑237 (2‑MAP) to Nevada’s Schedule I in conformity with federal scheduling. This adoption signals a binding scheduling update in the Nevada administrative rulemaking process; once effective/codified per Nevada procedures, regulated entities should treat these substances as Schedule I for compliance screening, handling controls, and related controlled substance obligations applicable under Nevada law.
European Commission update: second CRMA strategic projects selection round closes; 160+ applications including REE permanent magnet projects
The European Commission reported that the second selection round/call for Strategic Projects under the EU Critical Raw Materials Act (CRMA) has closed, with 160+ project applications. The update notes that 21 applications focus on rare earth elements (REEs) for permanent magnets. For compliance and supply-chain teams, this signals CRMA implementation progress and helps identify which REE/magnet projects may obtain (or be seeking) Strategic Project status, which can influence permitting timelines, due-diligence assumptions, and sourcing/ramp-up planning for REE permanent magnet supply chains.